Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Year-over-year earnings per share growth rate
5Y CAGR
-24.6%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.35% |
| Q3 2025 | 58.41% |
| Q2 2025 | 21.16% |
| Q1 2025 | -155.93% |
| Q4 2024 | 84.98% |
| Q3 2024 | -1352.51% |
| Q2 2024 | 97.17% |
| Q1 2024 | -123.72% |
| Q4 2023 | 73.81% |
| Q3 2023 | -71.41% |
| Q2 2023 | -41.56% |
| Q1 2023 | 52.11% |
| Q4 2022 | -4.28% |
| Q3 2022 | -5.06% |
| Q2 2022 | -21.09% |
| Q1 2022 | -3.75% |
| Q4 2021 | 0.35% |
| Q3 2021 | 14.92% |
| Q2 2021 | 13.49% |
| Q1 2021 | -66.01% |
| Q4 2020 | 46.43% |
| Q3 2020 | 43.29% |
| Q2 2020 | 37.87% |
| Q1 2020 | -17.06% |
| Q4 2019 | 13.42% |
| Q3 2019 | 9.15% |
| Q2 2019 | 39.66% |
| Q1 2019 | 6.20% |
| Q4 2018 | 51.00% |
| Q3 2018 | 2.33% |
| Q2 2018 | 19.52% |
| Q1 2018 | 38.24% |
| Q4 2017 | -30.77% |
| Q3 2017 | -12.07% |
| Q2 2017 | -2791.09% |
| Q1 2017 | 3.45% |
| Q4 2016 | 42.02% |
| Q3 2016 | 12.24% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |